IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1867
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$1.3B
Michael G. Raab
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation. It is also developing RDX013, a potassium secretagogue, for the. treatment of elevated serum potassium, or hyperkalemia, among certain patients with kidney and/or heart disease.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = ARDX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$ARDX ARDELYX, INC. | 51 | 61 | 52 | 51 | - | 31.7x | -37.1% | -12.4% | 87.8% | -14.3% | -19.2% | 50.7% | 0.0% | 121.0x | $1.3B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
ARDELYX, INC. (ARDX) receives a "Hold" rating with a composite score of 50.9/100. It ranks #1867 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Michael G. Raab
Chief Executive Officer
Labor Force
90
61
29
52
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for ARDX
In-line with peers — no strong momentum signal
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ARDX.
View All RatingsImproving capital utilization rates confirmed
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 61 | 60 | +1NEUTRAL |
| MOMENTUM | 51 | 38 | +13ALPHA |
| VALUATION | 52 | 31 | +21ALPHA |
| INVESTMENT | 29 | 32 | -3NEUTRAL |
| STABILITY | 52 | 38 | +14ALPHA |
| SHORT INT | 62 | 72 | -10DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -20.2% vs WACC 8.9% (spread -29.1%)
GM 88% vs sector 43%, OM -14% vs sector 1%
Capital turnover 2.54x, R&D intensity 17.6%
Rev growth 51%, 10yr history
Interest coverage -5.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns ARDELYX, INC. a Hold rating, with a composite score of 50.9/100 and 3 out of 5 stars. Ranked #1867 of 7,333 stocks, ARDX presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 61/100, ARDX shows adequate but unremarkable business quality. The company reports a return on equity of -37.1% (sector avg: -2.5%), gross margins of 87.8% (sector avg: 42.5%), net margins of -19.2% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
ARDX's value score of 52/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include an EV/EBITDA of 31.69x, a P/B ratio of 8.34x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
ARDELYX, INC.'s investment score of 29/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 50.7% vs. a sector average of 5.9% and a return on assets of -12.4% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ARDX demonstrates moderate momentum with a score of 51/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 50.7% year-over-year, while a beta of 0.58 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
With a stability score of 52/100, ARDX exhibits average financial resilience. Key stability metrics include a beta of 0.58 and a debt-to-equity ratio of 121.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
ARDX carries a short interest score of 62/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 121.00x), small-cap liquidity risk. At $1.3B market cap (small-cap), ARDELYX, INC. offers reasonable institutional liquidity.
ARDELYX, INC. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1867 of 7,333 overall (75th percentile). Key comparisons include ROE of -37.1% trailing the -2.5% sector median and operating margins of -14.3% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ARDX currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Investment (29) is the limiting factor — improvement here would lift the composite score most.
EV/EBITDA 177% ABOVE SECTOR MEDIAN
ROE 1398% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 107% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate ARDELYX, INC. (ARDX) as a Hold with a composite score of 50.9/100 at a current price of $6.56. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in quality (61th percentile) and stability (52th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (29th percentile) and momentum (51th percentile) tempers our overall conviction. We assign a Narrow Moat rating (43/100), High uncertainty, and Poor capital allocation.
Key items to watch: balance sheet deleveraging progress; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is widening, which provides additional comfort in the durability of the competitive position.
ARDELYX, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 50.9/100 places it at rank #1867 in our full 7,333-stock universe. At $1.3B in market capitalization, ARDELYX, INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 51%, though momentum at the 51th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 88% (+45.3pp vs sector) narrow to operating margins of -14% (-15.6pp vs sector) and net margins of -19.2%, yielding a gross-to-net conversion rate of -22%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $6.56, ARDELYX, INC. is trading near fair value based on current fundamentals. Our value factor score of 52/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at EV/EBITDA of 31.7x (at a premium), P/B of 8.3x, P/S of 3.7x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 88% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 51% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Elevated leverage (121% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Thin net margins of -19.2% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to ARDELYX, INC.. Key risk factors include significant leverage (121% debt-to-equity), current negative profitability (net margin -19.2%), low beta of 0.58 — while defensive, this may indicate limited upside participation in bull markets. The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: significant leverage (121% debt-to-equity); current negative profitability (net margin -19.2%); low beta of 0.58 — while defensive, this may indicate limited upside participation in bull markets; the combination of leverage (121% D/E) and thin margins (-19.2% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 52th percentile and quality factor at the 61th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 88% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate ARDELYX, INC.'s capital allocation as Poor. Key concerns include low returns on equity (-37.1%), negative profitability, weak asset returns (ROA -12.4%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — ARDELYX, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, ARDELYX, INC. receives a Hold rating with a composite score of 50.9/100 (rank #1867 of 7,333). Our quantitative framework assigns a Narrow Moat (43/100, trend: widening), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 49/100.
Our analysis supports a neutral stance on ARDELYX, INC.. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign ARDELYX, INC. a Narrow Moat rating with a composite moat score of 43/100. The ROIC-WACC spread of -29.1% is the primary signal of economic value creation. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that ARDELYX, INC. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being growth durability at 14.7/20.
The strongest moat sources are growth durability (14.7/20) and margin superiority (13.7/20). Rev growth 51%, 10yr history. GM 88% vs sector 43%, OM -14% vs sector 1%. These pillars form the core of ARDELYX, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0.5/20) and financial resilience (2.8/20). ROIC -20.2% vs WACC 8.9% (spread -29.1%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Widening. ROIC has trended upward at ~158.2pp per year, and operating margin trajectory confirms strengthening economics. ARDELYX, INC.'s competitive position is improving on a fundamental basis. We expect the moat score to drift upward if these trends persist over the next 12–18 months.
Key profit drivers include gross margins of 88% providing a solid profitability foundation, robust top-line growth of 51% expanding the revenue base. The margin cascade from 88% gross to -14% operating to -19.2% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 61th percentile.
The margin profile shows gross margins of 88%, operating margins of -14%, net margins of -19.2%. Return metrics include ROE of -37.1% and ROA of -12.4%. Relative to the Manufacturing sector, gross margins are 45.3 percentage points above the sector median of 43%, and ROE of -37.1% compares to a sector median of -2.5%.
The balance sheet reflects above-average leverage with D/E of 121%, revenue growth of 51%. The sector median D/E is 0%, putting ARDELYX, INC. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
First-of-its-kind partnership designed to educate and mobilize patients to imagine a healthier tomorrowDAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (Nasdaq: ARDX), a biopharmaceutical company with a vision of creating a healthier tomorrow for patients, today announced a multi-year partnership naming Ardelyx as an official corporate pharmaceutical Marketing Partner of the LPGA Tour. The exclusive partnership
You may be concerned about the recent declines in AI stocks such as NVDA.
In February 2026, Ardelyx, Inc. reported full-year 2025 revenue of US$407.32 million, up from US$333.62 million, while net loss widened to US$61.6 million, and issued 2026 revenue guidance for IBSRELA of US$410–US$430 million and XPHOZAH of US$110–US$120 million. Alongside this update, Ardelyx highlighted strong growth in IBSRELA sales, new patents extending protection to 2042, and ongoing late-stage development efforts that analysts cite as reinforcing the company’s longer-term product and...
Ardelyx (ARDX) is back in focus after its full year 2025 report showed revenue of US$407.32 million and a net loss of US$61.6 million, along with new 2026 revenue guidance. See our latest analysis for Ardelyx. The recent guidance and product updates have arrived after a sharp pullback, with a 7 day share price return of a 16.3% decline and a 30 day share price return of a 26% decline. Ardelyx still shows a 12.1% one year total shareholder return and a very large three year total shareholder...